SG EFF. CALL24 LLY | Real-time Bid/Ask 03:15:56 2024-07-16 am EDT | ||
| 1.13 EUR / 1.15 EUR | +3.64% |
|
| Current month | +19.57% | ||
| 1 month | +41.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 1.1 | +0.92% |
| 24-07-12 | 1.09 | +11.22% |
| 24-07-11 | 0.98 | -8.41% |
| 24-07-10 | 1.07 | +10.31% |
| 24-07-09 | 0.97 | +2.11% |
Delayed Quote BME
Last update July 15, 2024 at 11:30 am EDT
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| K9097 | |
| ISIN | DE000SW92596 |
| Date issued | 2024-05-14 |
| Maturity | 2024-12-20 (158 Days) |
| Parity | 100 : 1 |
| Emission price | 0.36 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.1 € |
|---|---|
| Lowest since issue | 0.33 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 7.9x |
| Moneyness | 0.000000 |
| Spread | 0.01 € |
| Spread % | 0.90% |
| Intrinsic value | 0.000000 |
| Present value | 1.140 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Warrants
- K9097 Warrant
